tiprankstipranks
Trending News
More News >
Liberta Co., Ltd. (JP:4935)
:4935
Japanese Market
Advertisement

Liberta Co., Ltd. (4935) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4935

Liberta Co., Ltd.

(4935)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
¥1,905.00
▲(1.60% Upside)
Liberta Co., Ltd.'s overall stock score is primarily impacted by financial performance challenges, including profitability and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. The lack of earnings call and corporate events data limits further insights.
Positive Factors
Revenue Growth
Strong revenue growth indicates effective market strategies and product demand, supporting long-term business expansion and competitiveness.
Product Distribution Channels
Diverse distribution channels enhance market reach and resilience, allowing the company to adapt to changing consumer behaviors and market conditions.
Gross Profit Margins
Healthy gross profit margins suggest strong pricing power and cost management, providing a foundation for future profitability improvements.
Negative Factors
Net Loss
A net loss impacts the company's ability to reinvest in growth and may challenge its financial stability, requiring strategic adjustments.
Cash Flow Challenges
Cash flow challenges can limit operational flexibility and investment capacity, potentially hindering long-term growth and stability.
Rising Debt Levels
Increased leverage can strain financial resources and elevate risk, impacting the company's ability to finance future growth initiatives.

Liberta Co., Ltd. (4935) vs. iShares MSCI Japan ETF (EWJ)

Liberta Co., Ltd. Business Overview & Revenue Model

Company DescriptionLiberta Co., Ltd. (4935) is a Japanese company primarily engaged in the development, manufacturing, and sale of healthcare products, focusing on innovative solutions for skin health and personal care. The company operates in the pharmaceutical and cosmetic sectors, providing a range of products that include topical treatments, skincare formulations, and health supplements. Liberta is committed to leveraging advanced research and technology to enhance consumer well-being and promote healthier skin.
How the Company Makes MoneyLiberta Co., Ltd. generates revenue through multiple streams, primarily from the sale of its skincare and healthcare products. The company distributes its products through various channels, including pharmacies, online platforms, and direct sales, catering to both individual consumers and healthcare professionals. Key revenue streams include prescription medications, over-the-counter skincare products, and health supplements. Additionally, Liberta may engage in strategic partnerships with healthcare providers, clinics, and distributors to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Liberta Co., Ltd. Financial Statement Overview

Summary
Liberta Co., Ltd. has shown strong revenue growth, but profitability is under pressure with a net loss in 2024. The balance sheet reflects increased leverage, and cash flow challenges suggest potential liquidity issues. Improvement in operational efficiency and cash flow management is needed.
Income Statement
70
Positive
Liberta Co., Ltd. showed solid revenue growth from 2023 to 2024 with a revenue increase of approximately 21.8%. Gross profit margins are healthy, but the company posted a net loss in 2024, impacting its net profit margin significantly. EBIT and EBITDA margins are relatively low, indicating potential challenges in operational efficiency.
Balance Sheet
65
Positive
The company's debt-to-equity ratio increased due to rising debt levels, indicating higher financial leverage. Return on equity has been impacted by negative net income in 2024. The equity ratio remains stable, showing a decent proportion of assets financed by equity.
Cash Flow
55
Neutral
Liberta Co., Ltd. experienced negative free cash flow growth and negative operating cash flow in 2024, raising concerns about cash management. The operating cash flow to net income ratio is negative, highlighting the issues with converting income into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.66B8.64B7.09B6.64B5.03B5.11B
Gross Profit3.55B3.34B2.85B2.60B2.15B2.18B
EBITDA108.18M259.90M318.19M308.32M286.75M284.08M
Net Income-160.41M-21.17M111.33M114.51M200.23M155.23M
Balance Sheet
Total Assets6.95B6.44B5.52B5.31B2.94B3.18B
Cash, Cash Equivalents and Short-Term Investments1.24B1.01B880.52M986.20M947.59M959.48M
Total Debt3.85B3.44B2.49B2.44B825.45M1.19B
Total Liabilities5.61B4.87B3.88B3.74B1.62B2.01B
Stockholders Equity1.33B1.57B1.63B1.57B1.32B1.16B
Cash Flow
Free Cash Flow0.00-624.92M311.02M-825.23M391.70M-156.13M
Operating Cash Flow0.00-577.34M414.13M-799.26M416.57M-150.71M
Investing Cash Flow0.00-202.74M-144.96M-692.94M-51.12M-26.93M
Financing Cash Flow0.00885.84M-400.30M1.51B-410.29M419.08M

Liberta Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1875.00
Price Trends
50DMA
1977.54
Negative
100DMA
2278.10
Negative
200DMA
1899.14
Positive
Market Momentum
MACD
-19.91
Negative
RSI
48.20
Neutral
STOCH
59.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4935, the sentiment is Negative. The current price of 1875 is below the 20-day moving average (MA) of 1963.70, below the 50-day MA of 1977.54, and below the 200-day MA of 1899.14, indicating a neutral trend. The MACD of -19.91 indicates Negative momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 59.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4935.

Liberta Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
¥35.90B25.751.66%0.22%4.15%
68
Neutral
¥10.92B21.615.77%22.86%-32.11%
63
Neutral
¥10.15B30.652.29%10.55%-56.55%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
52
Neutral
¥6.13B13.02-20.62%
49
Neutral
¥12.17B0.48%10.13%-14654.18%
45
Neutral
¥5.12B16.361.68%8.46%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4935
Liberta Co., Ltd.
1,892.00
749.90
65.66%
JP:4923
Cota Co., Ltd.
1,193.00
-409.27
-25.54%
JP:4926
C'BON COSMETICS Co., Ltd.
1,199.00
127.02
11.85%
JP:4932
Almado, Inc.
1,076.00
91.16
9.26%
JP:4934
Premier Anti-Aging Co., Ltd.
710.00
19.00
2.75%
JP:4936
AXXZIA, Inc.
410.00
-126.19
-23.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 28, 2025